

# Resource Summary Report

Generated by [RRID](#) on Sep 2, 2026

## PaTu 8902

RRID:CVCL\_1845

Type: Cell Line

### Proper Citation

RRID:CVCL\_1845

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_1845](https://web.expasy.org/cellosaurus/CVCL_1845)

**Proper Citation:** RRID:CVCL\_1845

**Description:** Cell line PaTu 8902 is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Female

**Disease:** Pancreatic adenocarcinoma

**Defining Citation:** [PMID:8194712](#), [PMID:8287116](#), [PMID:10700188](#), [PMID:11668190](#), [PMID:15126341](#), [PMID:15688027](#), [PMID:22460905](#), [PMID:25167228](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26216984](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29444439](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:35839778](#)

**Comments:** Population: Caucasian., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** PaTu 8902

**Synonyms:** PA-TU-8902, PATU-8902, PaTu8902, PATU8902, 8902, PaCL2

**Cross References:** BTO:BTO\_0006485, CLO:CLO\_0008382, EFO:EFO\_0006729, CLDB:cl3860, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID\_ORCS\_Cell\_line:191, BioSample:SAMN03473078, BioSample:SAMN10987803, cancercellines:CVCL\_1845, Cell\_Model\_Passport:SIDM00455, Cosmic:873004, Cosmic:948381, Cosmic:2434100,

Cosmic-CLP:1298526, DepMap:ACH-000599, DSMZ:ACC-179, DSMZCellDive:ACC-179, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1298526, GEO:GSM206534, GEO:GSM887502, GEO:GSM888584, GEO:GSM1670336, IARC\_TP53:2966, IARC\_TP53:25073, LiGeA:CCL\_026, LINCS\_LDP:LCL-1744, NCBI\_Iran:C557, PharmacDB:PATU8902\_1236\_2019, PRIDE:PXD030304, Progenetix:CVCL\_1845, Wikidata:Q54938318

**ID:** CVCL\_1845

**Record Creation Time:** 20220427T221412+0000

**Record Last Update:** 20260829T235548+0000

---

## Ratings and Alerts

No rating or validation information has been found for PaTu 8902.

No alerts have been found for PaTu 8902.

---

## Data and Source Information

**Source:** [CelloSaurus](#)

---

## Usage and Citation Metrics

We found 26 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#).

Zhang R, et al. (2026) Covalent modification of a glutamic acid inspired by HaloTag technology. Nature communications, 17(1), 1257.

Assi M, et al. (2026) Extracellular matrix sensing regulates intratumoral heterogeneity of autophagic flux. Cell, 189(6), 1731.

Zhang R, et al. (2026) Targeting a Glutamic Acid in PDE? with Fluoromethyl-Aryl Electrophiles Impairs K-Ras Signaling. Journal of medicinal chemistry.

Cunniff PJ, et al. (2025) KLF5 enables dichotomous lineage programs in pancreatic cancer via the AAA+ ATPase coactivators RUVBL1 and RUVBL2. Nature communications, 16(1), 9996.

Anastasio G, et al. (2025) Enhancing PDAC therapy: Decitabine-olaparib synergy targets KRAS-dependent tumors. iScience, 28(2), 111842.

Hang H, et al. (2025) SP1-Mediated Glycolytic Reprogramming Promotes Tumorigenesis and Progression in Pancreatic Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e10071.

Haastrup MO, et al. (2024) Mitochondrial Translocase TOMM22 Is Overexpressed in Pancreatic Cancer and Promotes Aggressive Growth by Modulating Mitochondrial Protein Import and Function. *Molecular cancer research : MCR*, 22(2), 197.

He C, et al. (2024) Vitamin B6 Competition in the Tumor Microenvironment Hampers Antitumor Functions of NK Cells. *Cancer discovery*, 14(1), 176.

Obajdin J, et al. (2024) Solid tumor immunotherapy using NKG2D-based adaptor CAR T cells. *Cell reports. Medicine*, 5(11), 101827.

Yoon SJ, et al. (2023) Comprehensive Metabolic Tracing Reveals the Origin and Catabolism of Cysteine in Mammalian Tissues and Tumors. *Cancer research*, 83(9), 1426.

Paul MC, et al. (2023) Non-canonical functions of SNAIL drive context-specific cancer progression. *Nature communications*, 14(1), 1201.

Zhao T, et al. (2023) Nuclear GRP78 Promotes Metabolic Reprogramming and Therapeutic Resistance in Pancreatic Ductal Adenocarcinoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(24), 5183.

Wei D, et al. (2023) Activation of Vitamin D/VDR Signaling Reverses Gemcitabine Resistance of Pancreatic Cancer Cells Through Inhibition of MUC1 Expression. *Digestive diseases and sciences*.

Köferle A, et al. (2022) Interrogation of cancer gene dependencies reveals paralog interactions of autosome and sex chromosome-encoded genes. *Cell reports*, 39(2), 110636.

Klemke L, et al. (2021) The Gain-of-Function p53 R248W Mutant Promotes Migration by STAT3 Deregulation in Human Pancreatic Cancer Cells. *Frontiers in oncology*, 11, 642603.

Biancur DE, et al. (2021) Functional Genomics Identifies Metabolic Vulnerabilities in Pancreatic Cancer. *Cell metabolism*, 33(1), 199.

Hilfenhaus G, et al. (2021) A High-Content Screen Identifies Drugs That Restrict Tumor Cell Extravasation across the Endothelial Barrier. *Cancer research*, 81(3), 619.

Banh RS, et al. (2020) Neurons Release Serine to Support mRNA Translation in Pancreatic Cancer. *Cell*, 183(5), 1202.

Hollinshead KER, et al. (2020) Respiratory Supercomplexes Promote Mitochondrial Efficiency and Growth in Severely Hypoxic Pancreatic Cancer. *Cell reports*, 33(1), 108231.

Nelson BS, et al. (2020) Tissue of origin dictates GOT1 dependence and confers synthetic lethality to radiotherapy. *Cancer & metabolism*, 8, 1.